Caris Life Sciences and Flatiron Health Partner to Vastly Increase Access to Most Comprehensive Molecular Testing Available
Txylo.com/10206634
Trending...
- Texas Center For Oral Surgery & Dental Implants Now Has Videography On Same Day Dental Implants
- Dogs at the Dentist: How an unlikely partnership is helping treat dental anxiety
- CORNERSTONE HOME LENDING WELCOMES NEIL MERRITT AS SENIOR VICE PRESIDENT OF PRODUCT STRATEGY & DEVELOPMENT
Partnership broadens precision medicine access at the point of care with seamless ordering and receipt of Caris molecular profiling results directly in patient records via the OncoEMR® platform
IRVING, Texas, Sept. 23, 2022 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, today announced a partnership with Flatiron Health, a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients, to integrate Caris' market leading molecular testing portfolio with OncoEMR®, a leading cloud-based electronic medical record (EMR) tool.
"The integration with OncoEMR is another milestone achievement along our goal of making personalized precision healthcare accessible to as many physicians and patients as possible," said David Spetzler, M.S., Ph.D., MBA, President and Chief Scientific Officer of Caris. "Delivering critical molecular results directly at the point of care in community oncology settings is paramount to every patient's ability to fight, and hopefully beat cancer. Integrating within the OncoEMR platform, which reaches almost 40 percent of all U.S. community oncologists, significantly aids in delivering on our commitment."
The Molecular Profiling Integration between OncoEMR and Caris enables data-driven clinical decision making for over 2,000 clinicians within the Flatiron network, made up of more than 800 unique cancer care locations across the country. Through the Molecular Profiling Integration, users can easily submit Caris orders with fewer clicks and less data entry, track real-time status updates, and receive the results directly within OncoEMR. This streamlines clinical workflows for physicians and offers access to Caris molecular reports in the same environment in which they develop care plans. In addition to presenting time-saving benefits within the clinician ordering process, the cloud-based integration is easily enabled–with no associated cost or development work–to any practice in the Flatiron network that wants it.
More on Txylo.com
"Insight into tumor biology enables precision medicine, and this Molecular Profiling Integration with Caris allows oncologists and their teams to efficiently order molecular profiling tests, track order status and view results, all without leaving OncoEMR. Simplifying the workflow can promote appropriate and equitable testing, eliminate redundant tests, minimize practice disruption, and surface therapeutic opportunities with the goal of better patient outcomes," said James Hamrick, Vice President Clinical Oncology at Flatiron Health. "We are thrilled for this partnership with Caris to further enhance delivering a better care experience for physicians and their patients, as we reimagine the infrastructure of cancer care."
Caris' entire suite of molecular profile services, including comprehensive whole exome and whole transcriptome sequencing, is now available for ordering within the OncoEMR network. Caris is the first and only partner with whole exome and whole transcriptome sequencing capabilities to integrate with Flatiron's OncoEMR and plans to continue collaborating with EMR/EHR systems across both academic and community oncology spaces on new ways to integrate genomic results into patient care and education.
About Caris Life Sciences
Caris Life Sciences® (Caris) is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale clinico-genomic database and cognitive computing needed to analyze and unravel the molecular complexity of disease. This information provides an unmatched resource and the ideal path forward to conduct the basic, fundamental research to accelerate discovery for detection, diagnosis, monitoring, therapy selection and drug development to improve the human condition.
With a primary focus on cancer, Caris' suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers better detect, diagnose and treat patients. Caris' latest advancement is a blood-based, circulating nucleic acids sequencing (cNAS) assay that combines comprehensive molecular analysis (Whole Exome and Whole Transcriptome Sequencing from blood) and serial monitoring – making it the most powerful liquid biopsy assay ever developed.
More on Txylo.com
Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Denver, Tokyo, Japan and Basel, Switzerland. Caris provides services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit CarisLifeSciences.com or follow us on Twitter (@CarisLS).
About Flatiron Health
Flatiron Health is a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients today and tomorrow. Through clinical and data science, we translate patient experiences into real-world evidence to improve treatment, inform policy, and advance research. Cancer is smart. Together, we can be smarter. Flatiron Health is an independent affiliate of the Roche Group. Flatiron.com @FlatironHealth
Caris Life Sciences Media Contact:
Lisa Burgner
[email protected]
214.294.5606
Flatiron Media Contact:
Nina Toor
[email protected]
SOURCE Caris Life Sciences
IRVING, Texas, Sept. 23, 2022 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, today announced a partnership with Flatiron Health, a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients, to integrate Caris' market leading molecular testing portfolio with OncoEMR®, a leading cloud-based electronic medical record (EMR) tool.
"The integration with OncoEMR is another milestone achievement along our goal of making personalized precision healthcare accessible to as many physicians and patients as possible," said David Spetzler, M.S., Ph.D., MBA, President and Chief Scientific Officer of Caris. "Delivering critical molecular results directly at the point of care in community oncology settings is paramount to every patient's ability to fight, and hopefully beat cancer. Integrating within the OncoEMR platform, which reaches almost 40 percent of all U.S. community oncologists, significantly aids in delivering on our commitment."
The Molecular Profiling Integration between OncoEMR and Caris enables data-driven clinical decision making for over 2,000 clinicians within the Flatiron network, made up of more than 800 unique cancer care locations across the country. Through the Molecular Profiling Integration, users can easily submit Caris orders with fewer clicks and less data entry, track real-time status updates, and receive the results directly within OncoEMR. This streamlines clinical workflows for physicians and offers access to Caris molecular reports in the same environment in which they develop care plans. In addition to presenting time-saving benefits within the clinician ordering process, the cloud-based integration is easily enabled–with no associated cost or development work–to any practice in the Flatiron network that wants it.
More on Txylo.com
- New Studies Show the Impact of e2L Coaching on Teacher Retention & Multilingual Learners' Outcomes
- The Five Pillars of Success Pillar One Strengths Outlined by Rosann Santos CPC
- InventHelp Inventor Develops Modified Line Divider for Roads (HOF-406)
- Pitch Black Appoints New Chief People Officer
- AIS Healthcare Celebrates International Volunteer Day
"Insight into tumor biology enables precision medicine, and this Molecular Profiling Integration with Caris allows oncologists and their teams to efficiently order molecular profiling tests, track order status and view results, all without leaving OncoEMR. Simplifying the workflow can promote appropriate and equitable testing, eliminate redundant tests, minimize practice disruption, and surface therapeutic opportunities with the goal of better patient outcomes," said James Hamrick, Vice President Clinical Oncology at Flatiron Health. "We are thrilled for this partnership with Caris to further enhance delivering a better care experience for physicians and their patients, as we reimagine the infrastructure of cancer care."
Caris' entire suite of molecular profile services, including comprehensive whole exome and whole transcriptome sequencing, is now available for ordering within the OncoEMR network. Caris is the first and only partner with whole exome and whole transcriptome sequencing capabilities to integrate with Flatiron's OncoEMR and plans to continue collaborating with EMR/EHR systems across both academic and community oncology spaces on new ways to integrate genomic results into patient care and education.
About Caris Life Sciences
Caris Life Sciences® (Caris) is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale clinico-genomic database and cognitive computing needed to analyze and unravel the molecular complexity of disease. This information provides an unmatched resource and the ideal path forward to conduct the basic, fundamental research to accelerate discovery for detection, diagnosis, monitoring, therapy selection and drug development to improve the human condition.
With a primary focus on cancer, Caris' suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers better detect, diagnose and treat patients. Caris' latest advancement is a blood-based, circulating nucleic acids sequencing (cNAS) assay that combines comprehensive molecular analysis (Whole Exome and Whole Transcriptome Sequencing from blood) and serial monitoring – making it the most powerful liquid biopsy assay ever developed.
More on Txylo.com
- Emmy Award Winning Journalist Joins Prominent Haddonfield Real Estate Agency
- Crescent Energy Announces Offering of $150 Million Private Placement of Additional 9.250% Senior Notes Due 2028
- Renew and Lantower Residential Announce Partnership
- Founder Brings Inaugural Event To Braselton Georgia At Legendary Resort and Winery
- HBCUs Among Groups Heading to The Bahamas for Track & Field Competition in March 2024
Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Denver, Tokyo, Japan and Basel, Switzerland. Caris provides services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit CarisLifeSciences.com or follow us on Twitter (@CarisLS).
About Flatiron Health
Flatiron Health is a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients today and tomorrow. Through clinical and data science, we translate patient experiences into real-world evidence to improve treatment, inform policy, and advance research. Cancer is smart. Together, we can be smarter. Flatiron Health is an independent affiliate of the Roche Group. Flatiron.com @FlatironHealth
Caris Life Sciences Media Contact:
Lisa Burgner
[email protected]
214.294.5606
Flatiron Media Contact:
Nina Toor
[email protected]
SOURCE Caris Life Sciences
Filed Under: Business
0 Comments
Latest on Txylo.com
- Workplace Morale and Stock Performance - FRGT
- SSV Network selects Randamu for Distributed Key Generation (DKG) Grant Award
- Whistleblowers Reveal Disturbing Details of Houston-Area Massage Envy Sexual Assaults as More Women Come Forward
- Texas: Governor Abbott Announces Governor's Small Business Summit In Houston
- Lawmato relaunches its virtual consultation app with enhanced features
- T.X. Troan Announces the Release of Sophia Freeman and the Winter Behemoth
- Texas: Governor Abbott Statement On The Passing Of Justice Sandra Day O'Connor
- Journey to Bethlehem by Joseph Guy - Religion & Spirituality
- MiBOXER Is Exhibiting At Hong Kong International Autumn Lighting Fair
- Mammogen to Showcase New Data at SABCS 2023 Demonstrating Clinical Efficacy of Its genTRU-breast™ qPCR Blood Test in Early-Stage Breast Cancer
- Beck Properties Group, eXp Realty Expands Service in Southeast Indiana
- Stonely Unleashes Innovative Platform for Homeowners: Design and Order Kitchen Countertops Online with Ease!
- One Million Pages Read in the First Year !!
- Kingston NY-Based Ryan & Ryan Kicks Off its 65th Anniversary Dec. 6 by Underwriting a Chamber of Commerce Mixer Saluting RUPCO
- AECOM earns Equality 100 Award on the Human Rights Campaign Foundation's 2023 Corporate Equality Index
- The Murray Microschool For Arts
- This Week in Travel News: 12 Stories You Need to See
- Tobu Railway's Hosts "Tokyo Downtown Tour: Bamboo Lighting."
- "Street Fighter™ 6" Panel Announced for December 2nd at Los Angeles Comic Con; The Music of Street Fighter 6: A Special Look at the Video Game
- Texas Center For Oral Surgery & Dental Implants Now Has Videography On Same Day Dental Implants